- AMD Day 2014
- Research team
- Our research programme
- Our research in the media
- Frequently asked questions (FAQ)
- Contact us
- Seminar series
- Join the team - opportunities and vacancies
- July 2013 -'Big leap' towards curing blindness in stem cell study
- April 2012 - Photoreceptor transplants restore vision in mice
Our latest blog posts
Gene therapies for diabetic eye disease
Diabetes harms the retina and is a leading cause of severe sight impairment. Find out about how you can support our work and help develop effective therapies.
Current treatments for diabetic eye disease can help some people to some extent but do not work reliably and have harmful side effects. We aim to develop new treatments that can protect the circulation in the retina and promote the healthy function of its nerves. We are working to understand the ways that diabetes can harm the retina and to develop new treatments, including gene and cell therapies.
Diabetic eye disease shares many features with AMD, with the growth of abnormal and leaky blood vessels common to both. Current treatments are not effective for all patients and have significant side effects, which means developing gene delivery to control the growth of abnormal and leaky blood vessels is an attractive option (Bainbridge et al 2003).
We are also investigating the role of oxygen in diabetic eye disease (Lange et al 2011), as disturbances to the delivery and usage of oxygen caused by diabetes are an important factor in the damaging growth of new blood vessels. We have shown that a molecule that helps regulate how cells respond to a lack of oxygen, known as HIF-1, plays a crucial role in the growth of abnormal and leaky blood vessels (Mowat et al 2010). Together these results show the important role that the control of oxygen levels in the retina plays in diabetic eye disease as well as in AMD and may help identify new drug targets.
We have shown proof-of-concept that gene delivery of the sFlt1 gene can reduce the growth of abnormal blood vessels in a diabetes disease model (Bainbridge et al 2002). A clinical trial of AAV-sFlt1 delivery is now being carried out by a group in Australia
Page last modified on 05 feb 13 10:02